Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 1,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Macular Degeneration
Interventions: JSM6427; Drug
Lead sponsor: Jerini Ophthalmic; Industry
Eligibility: 50 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 9
States / cities: Beverly Hills, California • Boston, Massachusetts • Royal Oak, Michigan + 6 more

Conditions: Retinitis Pigmentosa
Interventions: Low Dose NT-501, High Dose NT-501; Combination Product
Lead sponsor: Neurotech Pharmaceuticals; Industry
Eligibility: 18 Years to 68 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 11
States / cities: Beverly Hills, California • Sacramento, California • San Francisco, California + 8 more

Conditions: Retinal Detachment
Interventions: Triamcinolone Acetonide 40mg/mL; Drug
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 19 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Diabetic Retinopathy, DR
Interventions: Standard of Care, Aflibercept; Drug
Lead sponsor: AbbVie; Industry
Eligibility: Not listed
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 20
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 17 more

Conditions: Age-related Macular Degeneration, Depression
Interventions: BA-LVR, ST-LVR; Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 65 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Solid Tumors With PTCH1 Loss-of-function Mutations
Interventions: ENV-101 (taladegib); Drug
Lead sponsor: Endeavor Biomedicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 16
States / cities: Los Angeles, California • Santa Rosa, California • Tampa, Florida + 13 more

Conditions: Inherited Ophthalmic Diseases, Hypopigmentation Disorder, Corneal Dystrophy, Blue-cone Monochromacy, Best Disease, Aniridia, Albinism
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 1 Day to 120 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2054
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Neovascular Age-elated Macular Degeneration (Wet AMD), Exudative Macular Degeneration
Interventions: LFG316, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Tucson, Arizona • Torrance, California • Fort Myers, Florida + 4 more

Conditions: Age-Related Macular Degeneration, Genetic Testing, Nutritional Biomarkers
Interventions: Early disclosure of genetic testing results, Late disclosure of genetic testing results; Behavioral
Lead sponsor: Paul S. Bernstein; Other
Eligibility: 18 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Age-Related Macular Degeneration
Interventions: Fluocinolone Acetonide; Drug
Lead sponsor: Alimera Sciences; Industry
Eligibility: 55 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
Interventions: Ultevursen, Sham-procedure; Drug · Other
Lead sponsor: Laboratoires Thea; Industry
Eligibility: 12 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 10
States / cities: San Diego, California • San Francisco, California • Miami, Florida + 7 more

Conditions: Wet Macular Degeneration, Wet Age-related Macular Degeneration
Interventions: Ziv-Aflibercept 25 MG/ML [Zaltrap], Ranibizumab; Drug
Lead sponsor: Kapil Kapoor; Other
Eligibility: 50 Years to 99 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Virginia Beach, Virginia

Conditions: Neovascular (Wet) Age-related Macular Degeneration
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2,079 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Uveitis, Cystoid Macular Edema
Interventions: Pegaptanib; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Retinopathy of Prematurity
Interventions: No intervention administered.; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: Up to 1 Year
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2030
U.S. locations: 5
States / cities: Palo Alto, California • Chicago, Illinois • Royal Oak, Michigan + 2 more

Conditions: Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis, Ovarian Vein Thrombosis, Renal Vein Thrombosis, Retinal Vein Thrombosis
Interventions: Direct Oral Anticoagulants; Drug
Lead sponsor: University of Malta; Other
Eligibility: 18 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Macular Degeneration, Maculopathy, Age-Related
Interventions: anecortave acetate; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 50 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Cidofovir, Probenecid, Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 12
States / cities: Los Angeles, California • Miami, Florida • Atlanta, Georgia + 7 more

Conditions: Assess Eye Measurements in Patients Having Retina Pathology or Glaucoma
Interventions: Not listed
Lead sponsor: Optovue; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 3
States / cities: Daly City, California • Petaluma, California • Walnut Creek, California

Conditions: Dry Eye Syndromes, Age-Related Macular Degeneration, Omega 3 Index
Interventions: OmegaBoost, Nature Made (soft gel), Nature Made (gummy); Dietary Supplement
Lead sponsor: Western University of Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Pomona, California

Conditions: Brain Injuries, Traumatic
Interventions: Head and Intraocular Trauma Tool; Device
Lead sponsor: Rebiscan, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Carcinoid, Neuroendocrine
Interventions: Seneca Valley Virus (biological agent); Drug
Lead sponsor: Neotropix; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 10
States / cities: Ocoee, Florida • Indianapolis, Indiana • Baltimore, Maryland + 7 more

Conditions: Parkinson's Disease
Interventions: Not listed
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Retinitis Pigmentosa
Interventions: Observation; Diagnostic Test
Lead sponsor: Shire; Industry
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD

A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa

Using Triamcinolone Acetonide to Reduce Pain After Scleral Buckle Surgery

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy

Low Vision Depression Prevention Trial for Age Related Macular Degeneration

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases

Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

The Moran AMD Genetic Testing Assessment Study

Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy

Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

Ziv-aflibercept Efficacy in Better Regulating AMD

Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)

Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema

Clinical and Genetic Analysis of ROP

DOAC in Unusual Site Venous Thrombosis

An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD

Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis

Evaluation of OCT Measurements

Efficacy of OmegaBoost to Increase Omega-3 Levels in Healthy Individuals

mTBI Identification and Monitoring Through Retinal Scanning

Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features

Relationship Between Symptoms, Retinal Morphology, and the Nigrostriatal Dopamine System in Parkinson's Disease

Observational Natural History Study of Autosomal Dominant Retinitis Pigmentosa (adRP)